Vertex Pharmaceuticals Rating Reiterated by UBS AG (VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX)‘s stock had its “buy” rating reaffirmed by investment analysts at UBS AG in a note issued to investors on Wednesday, Stock Ratings Network reports. They currently have a $84.00 target price on the stock. UBS AG’s target price would suggest a potential upside of 8.94% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Goldman Sachs Group Inc. raised their price target on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from $79.00 to $85.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Oppenheimer initiated coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research note to investors on Wednesday, August 21st. They set an “outperform” rating and a $105.00 price target on the stock. Finally, analysts at Cowen and Company raised their price target on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from $80.00 to $88.00 in a research note to investors on Tuesday, July 30th. They now have a “market perform” rating on the stock.
One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seventeen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $89.84.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 1.18% during mid-day trading on Wednesday, hitting $77.11. The stock had a trading volume of 1,685,843 shares. Vertex Pharmaceuticals has a one year low of $38.44 and a one year high of $89.96. The stock has a 50-day moving average of $78.04 and a 200-day moving average of $73.28. The company’s market cap is $17.952 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, July 29th. The company reported ($0.26) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.18) by $0.08. The company had revenue of $310.80 million for the quarter, compared to the consensus estimate of $308.02 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. The company’s revenue for the quarter was down 25.7% on a year-over-year basis. Analysts expect that Vertex Pharmaceuticals will post $-2.43 EPS for the current fiscal year.
In other Vertex Pharmaceuticals news, EVP Peter Mueller unloaded 7,500 shares of Vertex Pharmaceuticals stock on the open market in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $77.22, for a total value of $579,150.00. Following the sale, the executive vice president now directly owns 144,400 shares in the company. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.